Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Asbestos-Related Disease | Research

Expression of microRNAs in leukocytes and serum of asbestosis patients

Authors: Vivien Kauschke, Monika Philipp-Gehlhaar, Joachim Schneider

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Although asbestos use is banned in many countries, long latency of asbestos-related diseases like pleural plaques or asbestosis mean it is still a public health issue. People suffering from these diseases have a higher risk of developing mesothelioma or lung cancer, which can progress quickly and aggressively. MicroRNAs were suggested as potential biomarkers in several diseases. However, in asbestosis, blood microRNAs are less explored. Since miR-32-5p, miR-143-3p, miR-145-5p, miR-146b-5p, miR-204-5p and miR-451a are involved in fibrotic processes and in cancer, expression of these microRNAs was analyzed in leukocytes and serum of asbestosis patients.

Methods

MicroRNA expression was analyzed in leukocytes and serum of 36 patients (26 affected by pleural plaques and 10 by asbestosis) and 15 healthy controls by real-time RT-PCR. Additionally, data analyses were performed regarding disease severity based on ILO classification.

Results

MicroRNA miR-146b-5p was significantly down-regulated in leukocytes of patients suffering from pleural plaques with a large effect indicated by η2p = 0.150 and Cohen’s f = 0.42, a value of difference of 0.725 and a 95% confidence interval of 0.070–1.381. In patients suffering from asbestosis miR-146b-5p was not significantly regulated. However, data analyses considering disease severity only, revealed that miR-146b-5p was significantly down-regulated in leukocytes of mildly diseased patients compared to controls with a large effect indicated by η2p = 0.178 and Cohen’s f = 0.465, a value of difference of 0.848 and a 95% confidence interval of 0.097–1.599. Receiver operating characteristic (ROC) curve and an area under the ROC curve value of 0.757 for miR-146b-5p indicated acceptable discrimination ability between patients suffering from pleural plaques and healthy controls. Less microRNAs were detectable in serum than in leukocytes, showing no significant expression differences in all participants of this study. Moreover, miR-145-5p was regulated significantly differently in leukocytes and serum. An R2 value of 0.004 for miR-145-5p indicated no correlation in microRNA expression between leukocytes and serum.

Conclusion

Leukocytes seem more suitable than serum for microRNA analyses regarding disease and potentially cancer risk assessment of patients suffering from asbestos-related pleural plaques or asbestosis. Long-term studies may reveal whether down-regulation of miR-146b-5p in leukocytes might be an early indicator for an increased cancer risk.
Literature
1.
Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K. The current understanding of asbestos-induced epigenetic changes associated with lung cancer. Lung Cancer. 2020;11:1–11.PubMedPubMedCentral
2.
Commission E. Communication from the commission to the European Parliament, the council, the European economic and social committee and the Committee of the regions on working towards an asbestos-free future: a European approach to addressing the health risks of asbestos. European Commission; 2022. file:///C:/Users/jlu-su/Downloads/COM_2022_488_1_EN_ACT_part1_v5.pdf
3.
4.
Marsili D, Terracini B, Santana VS, Ramos-Bonilla JP, Pasetto R, Mazzeo A, Loomis D, Comba P, Algranti E. Prevention of asbestos-related disease in countries currently using asbestos. Int J Environ Res Public Health. 2016;13(5):494.PubMedPubMedCentralCrossRef
5.
Bersimbaev R, Bulgakova O, Aripova A, Kussainova A, Ilderbayev O. Role of microRNAs in lung carcinogenesis induced by asbestos. J Pers Med. 2021;11(2):97.PubMedPubMedCentralCrossRef
6.
Society AT. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691–715.CrossRef
7.
Pairon J-C, Laurent F, Rinaldo M, Clin B, Andujar P, Ameille J, Brochard P, Chammings S, Ferretti G, Galateau-Sallé F, et al. Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer Inst. 2013;105(4):293–301.PubMedCrossRef
8.
Gevenois P, de Maertelaer V, Madani A, Winant C, Sergent G, De Vuyst P. Asbestosis, pleural plaques and diffuse pleural thickening: three distinct benign responses to asbestos exposure. Eur Respir J. 1998;11(5):1021–7.PubMedCrossRef
9.
10.
Mukherjee S, de Klerk N, Palmer LJ, Olsen NJ, Pang SC, William MA. Chest pain in asbestos-exposed individuals with benign pleural and parenchymal disease. Am J Respir Crit Care Med. 2000;162(5):1807–11.PubMedCrossRef
11.
Hillerdal G. Pleural plaques and risk for bronchial carcinoma and mesothelioma. A prospective study. Chest. 1994;105(1):144–50.PubMedCrossRef
12.
Hillerdal G, Henderson DW. Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health. 1997;23(2):93–103.PubMedCrossRef
13.
Helmig S, Belwe A, Schneider J. Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J Investig Med. 2009;57(5):655–61.PubMedCrossRef
14.
Helmig S, Döhrel J, Schneider J. Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. Int J Mol Med. 2010;26(1):143–9.PubMedCrossRef
15.
Helmig S, Aliahmadi N, Schneider J. Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases. Biomarkers. 2010;15(5):400–9.PubMedCrossRef
16.
Helmig S, Grossmann M, Wübbeling J, Schneider J. Interleukin gene polymorphisms in pneumoconiosis. Int J Mol Med. 2012;30(2):401–8.PubMedCrossRef
17.
Helmig S, Dopp E, Wenzel S, Walter D, Schneider J. Induction of altered mRNA expression profiles caused by fibrous and granular dust. Mol Med Rep. 2014;9(1):217–28.PubMedCrossRef
18.
Helmig S, Walter D, Putzier J, Maxeiner H, Wenzel S, Schneider J. Oxidative and cytotoxic stress induced by inorganic granular and fibrous particles. Mol Med Rep. 2018;17(6):8518–29.PubMed
19.
Nagai H, Toyokuni S. Biopersistent fiber-induced inflammation and carcinogenesis: lessons learned from asbestos toward safety of fibrous nanomaterials. Arch Biochem Biophys. 2010;502(1):1–7.PubMedCrossRef
20.
Weber DG, Johnen G, Bryk O, Jöckel KH, Brüning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma–a pilot study. PLoS ONE. 2012;7(1): e30221.PubMedPubMedCentralCrossRef
21.
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.PubMedCrossRef
22.
Pogribny IP. MicroRNAs as biomarkers for clinical studies. Exp Biol Med. 2018;243(3):283–90.CrossRef
23.
Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68(23):2577–84.PubMedCrossRef
24.
Pascut D, Krmac H, Gilardi F, Patti R, Calligaris R, Crocè LS, Tiribelli C. A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients. Sci Rep. 2019;9(1):8265.PubMedPubMedCentralCrossRef
25.
Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008;132(1):9–14.PubMedCrossRef
26.
27.
Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009;55(11):1977–83.PubMedCrossRef
28.
Siracusa J, Koulmann N, Bourdon S, Goriot M-E, Banzet S. Circulating miRNAs as biomarkers of acute muscle damage in rats. Am J Pathol. 2016;186(5):1313–27.PubMedCrossRef
29.
Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, Jen Lee M, Galas DJ, Wang K. The MicroRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–41.PubMedPubMedCentralCrossRef
30.
Solé C, Moliné T, Vidal M, Ordi-Ros J, Cortés-Hernández J. An exosomal urinary miRNA signature for early diagnosis of renal fibrosis in lupus nephritis. Cells. 2019;8(8):773.PubMedPubMedCentralCrossRef
31.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–5.PubMedCrossRef
32.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.PubMedPubMedCentralCrossRef
33.
Habib EM, Nosiar NA, Eid MA, Taha AM, Sherief DE, Hassan AE, Abdel Ghafar MT. MiR-150 expression in chronic myeloid leukemia: relation to imatinib response. Lab Med. 2021;53(1):58–64.CrossRef
34.
Habib EM, Nosiar NA, Eid MA, Taha AM, Sherief DE, Hassan AE, Abdel Ghafar MT. Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia. J Investig Med. 2021;69(2):333–7.PubMedCrossRef
35.
Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103(5):693–700.PubMedPubMedCentralCrossRef
36.
Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn. 2014;16(4):418–30.PubMedCrossRef
37.
Wang HJ, Liu H, Lin YH, Zhang SJ. MiR-32-5p knockdown inhibits epithelial to mesenchymal transition and renal fibrosis by targeting SMAD7 in diabetic nephropathy. Hum Exp Toxicol. 2021;40(4):587–95.PubMedCrossRef
38.
Mu S, Kang B, Zeng W, Sun Y, Yang F. MicroRNA-143-3p inhibits hyperplastic scar formation by targeting connective tissue growth factor CTGF/CCN2 via the Akt/mTOR pathway. Mol Cell Biochem. 2016;416(1):99–108.PubMedCrossRef
39.
Condorelli AG, Logli E, Cianfarani F, Teson M, Diociaiuti A, El Hachem M, Zambruno G, Castiglia D, Odorisio T. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts. Br J Dermatol. 2019;181(5):1017–27.PubMedCrossRef
40.
Ye Q, Liu Q, Ma X, Bai S, Chen P, Zhao Y, Bai C, Liu Y, Liu K, Xin M, et al. MicroRNA-146b-5p promotes atrial fibrosis in atrial fibrillation by repressing TIMP4. J Cell Mol Med. 2021;25(22):10543–53.PubMedPubMedCentralCrossRef
41.
Zhu L, Chen Y, Chen M, Wang W. Mechanism of miR-204-5p in exosomes derived from bronchoalveolar lavage fluid on the progression of pulmonary fibrosis via AP1S2. Ann Transl Med. 2021;9(13):1068.PubMedPubMedCentralCrossRef
42.
43.
Zhang JX, Yang W, Wu JZ, Zhou C, Liu S, Shi HB, Zhou WZ. MicroRNA-32-5p inhibits epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting SMAD family 3. J Cancer. 2021;12(8):2258–67.PubMedPubMedCentralCrossRef
44.
Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene. 2014;33(46):5319–31.PubMedCrossRef
45.
Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, Xu S. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med. 2015;36(6):1720–6.PubMedCrossRef
46.
Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao C, Wang C, Liu J, Li X, Dong M, et al. MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer. J Cancer. 2017;8(9):1704–16.PubMedPubMedCentralCrossRef
47.
Shen YY, Cui JY, Yuan J, Wang X. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci. 2018;22(17):5554–61.PubMed
48.
Zhou JH, Yao ZX, Zheng Z, Yang J, Wang R, Fu SJ, Pan XF, Liu ZH, Wu K. G-MDSCs-derived exosomal miRNA-143-3p promotes proliferation via targeting of ITM2B in lung cancer. Onco Targets Ther. 2020;13:9701–19.PubMedPubMedCentralCrossRef
49.
ILO. Guidelines for the use of the ILO international classification of radiographs of pneumoconiosis. Geneva: International Labor Office; 2011.
50.
Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–6.PubMedCrossRef
51.
Le Bouffant L. Investigation and analysis of asbestos fibers and accompanying minerals in biological materials. Environ Health Perspect. 1974;9:149–53.PubMedPubMedCentralCrossRef
52.
Reid A, de Klerk N, Ambrosini GL, Olsen N, Pang SC, Berry G, Musk AW. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. Occup Environ Med. 2005;62(12):885–9.PubMedPubMedCentralCrossRef
53.
Bhandari J, Thada PK, Sedhai YR. Asbestosis. St. Petersburg: StatPearls Publishing LLC; 2021.
54.
Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, et al. MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study. Dis Markers. 2017;2017:9645940.PubMedPubMedCentralCrossRef
55.
Kopylev L, Christensen KY, Brown JS, Cooper GS. A systematic review of the association between pleural plaques and changes in lung function. Occup Environ Med. 2015;72(8):606–14.PubMedCrossRef
56.
Van Keuren-Jensen KR, Malenica I, Courtright AL, Ghaffari LT, Starr AP, Metpally RP, Beecroft TA, Carlson EWJ, Kiefer JA, Pockros PJ, et al. microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver Int. 2016;36(3):334–43.PubMedCrossRef
57.
Weber DG, Gawrych K, Casjens S, Brik A, Lehnert M, Taeger D, Pesch B, Kollmeier J, Bauer TT, Johnen G, et al. Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma. Dis Markers. 2017;2017:9280170.PubMedPubMedCentralCrossRef
58.
59.
Waters CM, Roan E, Navajas D. Mechanobiology in lung epithelial cells: measurements, perturbations, and responses. Compr Physiol. 2012;2(1):1–29.PubMedPubMedCentral
60.
61.
Meder B, Backes C, Haas J, Leidinger P, Stähler C, Großmann T, Vogel B, Frese K, Giannitsis E, Katus HA, et al. Influence of the confounding factors age and sex on microRNA profiles from peripheral blood. Clin Chem. 2014;60(9):1200–8.PubMedCrossRef
62.
Cacchiarelli D, Legnini I, Martone J, Cazzella V, D’Amico A, Bertini E, Bozzoni I. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med. 2011;3(5):258–65.PubMedPubMedCentralCrossRef
Metadata
Title
Expression of microRNAs in leukocytes and serum of asbestosis patients
Authors
Vivien Kauschke
Monika Philipp-Gehlhaar
Joachim Schneider
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01129-z

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

Research

Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma

Review

Role of telitacicept in the treatment of IgA nephropathy

Review

The impact of music listening intervention on Asia elderly with dementia: a systematic review

Research

High return to sports rates after operative treatment of patella fractures

Research

Effects of the abdominal fat distribution on the relationship between exposure to air pollutants and thyroid hormones among Korean adult males